ARS Pharmaceuticals, Inc. Contract Liability (Deferred Revenue)
ARS Pharmaceuticals, Inc. (SPRY) had Contract Liability (Deferred Revenue) of $535.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-13
- 2026-06-30: Contract with Customer, Liability, Current $535.00K.
- 2026-03-31: Contract with Customer, Liability, Current $757.00K.
- 2025-12-31: Contract with Customer, Liability, Current $609.00K.
- 2025-09-30: Contract with Customer, Liability, Current $526.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $535.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $757.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $609.00K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $526.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $746.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $540.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $557.00K 10-K · filed 2026-03-09 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 |
| 2023-03-31 | $10.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $283.00K 10-K · filed 2024-03-21 |
| 2021-12-31 | $1.46M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |